Abstract
Thiazolidinediones (TZDs), synthetic ligands for the nuclear receptor PPAR³, have been largely used in the treatment of metabolic diseases such as insulin resistance, dyslipidemias and metabolic syndrome. These drugs were shown to improve glucose homeostasis by promoting fat redistribution from visceral to subcutaneous depots, adiponectin secretion and by reducing lipemia, lipotoxicity, a…